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Abstract
Background: Primary care reform in Ontario, Canada started with the introduction of new enrollment models, the
two largest of which are Family Health Networks (FHNs), a capitation-based model, and Family Health Groups
(FHGs), a blended fee-for-service model. The purpose of this study was to evaluate differences in performance
between FHNs and FHGs and to compare performance before and after physicians joined these new primary care
groups.
Methods: This study used Ontario administrative claims data to compare performance measures in FHGs and
FHNs. The study population included physicians who belonged to a FHN or FHG for at least two years. Patients
were included in the analyses if they enrolled with a physician in the two years after the physician joined a FHN or
FHG, and also if they saw the physician in a two year period prior to the physician joining a FHN or FHG.
Performance was derived from the administrative data, and included measures of preventive screening for cancer
(breast, cervical, colorectal) and chronic disease management (diabetes, heart failure, asthma).
Results: Performance measures did not vary consistently between models. In some cases, performance
approached current benchmarks (Pap smears, mammograms). In other cases it was improving in relation to
previous measures (colorectal cancer screening). There were no changes in screening for cervical cancer or breast
cancer after joining either a FHN or FHG. Colorectal cancer screening increased in both FHNs and FHGs. After
enrolling in either a FHG or a FHN, prescribing performance measures for diabetes care improved. However, annual
eye examinations decreased for younger people with diabetes after joining a FHG or FHN. There were no changes
in performance measures for heart failure management or asthma care after enrolling in either a FHG or FHN.
Conclusions: Some improvements in preventive screening and diabetes management which were seen amongst
people after they enrolled may be attributed to incentive payments offered to physicians within FHGs and FHNs.
However, these primary care delivery models need to be compared with other delivery models and fee for service
practices in order to describe more specifically what aspects of model delivery and incentives affect care.
Background
It has been increasingly recognized that health care sys-
tems with a strong primary care component are more
efficient and better able to handle current and future
health care pressures [1-3]. This has led to several pri-
mary care reform strategies in the United Kingdom
(UK), Australia, the United States (US) and Canada.
Common to all of these reform strategies is a movement
away from providing service based on a fee-for-service
payment system to a more blended payment mechanism
which includes incentives for improving quality and
performance.
In the late 1990s, the National Health Services (NHS)
in the UK refocused health care delivery through the
development of Primary Care Trusts which became
responsible for budgets of all hospital, community and
general medical services [4]. At the same time there was
the formation of the National Institute for Health and
Clinical Excellence which established clinical guidelines
on the appropriate care for people with specific disease
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mance contracts for family physicians (FPs). On this
system, a graduated scale of payments is provided in
proportion to an achieved benchmark of a quality of
care indicator. Additional NHS reforms in 2010
empower FPs with health care spending and change the
emphasis of performance measures to clinical outcomes.
Similarly in Australia, the Practice Incentives Program
(PIP), started in 1998, was an effort to support quality
improvement activities [5]. Over the years this program
has evolved to include a range of outcome-based perfor-
mance incentives and disease specific incentives.
Health care reform drives many debates under the
current political administration in the US. Included in
this debate are various physician incentives which pay
for quality rather than quantity in healthcare. The
reform document signed in March 2010 encourages the
implementation of physician payments which enhance
primary care services to improve quality of care, mostly
within the Medicare population [6].
Canada started to reform its primary care delivery sys-
tem after the release of the Romanow report in 2002
[7]. In Ontario, the largest province in Canada, the Min-
istry of Health and Long-Term Care (MOHLTC) intro-
duced two new primary care enrollment models. Family
Health Groups (FHGs) are a blended fee-for-service
model. The FHGs offer enhanced fee-for-service pay-
ments and new billing codes. This includes service
enhancement fees for having patients who meet bench-
mark targets for cervical, breast and colorectal cancer
screening. In 2006, FHGs were eligible to receive an
annual diabetes (DM) management incentive payment
of $60. For this fee FPs within a FHG need to complete
a MOHTLC DM flowsheet which documents several
required elements (medications, ophthalmology screen-
ing, laboratory testing) for their DM patients. This DM
flowsheet includes elements of DM management consis-
tent with the Canadian Diabetes Association 2003 Clini-
cal Practice Guidelines. FHNs are a blended capitation-
based model. The FHNs include a base payment per
patient for the provision of comprehensive care (capita-
tion) plus incentives, premiums and bonuses for preven-
tive care and some chronic disease management. While
the FHN model includes the same service enhancement
fees for cervical, breast and colorectal cancer screening
as FHGs, there are additional reminder fee payments
within the FHN model to contact patients for cervical,
breast and colorectal cancer screening. The FHN models
received the same annual DM incentive payment for the
completion of a flowsheet. In 2008, an annual heart fail-
ure (HF) management incentive was introduced for both
FHGs and FHNs, similar to the DM incentive. There
are no incentive payments for the management of any
other chronic diseases.
While information is emerging on the impact of
different payment mechanisms on physician behavior [8],
primary care reform in Ontario, Canada has provided a
natural experiment to assess the impact of a capitation-
based remuneration system (FHN) to a fee-for-service sys-
tem (FHG). It also prompts an examination within both
FHGs and FHNs of the introduction of incentives (for pre-
ventive care and some chronic disease management).
In Canada, performance measurements and quality of
care indicators have been developed for the attributes
and components of primary care medicine [9,10]. The
application of these measures are wide ranging and
serve to provide valuable feedback on improving quality
care, identifying care deficits in vulnerable populations,
and provide information to policy makers on program
planning. Existing health administrative data have been
a source of information for several preventive care and
chronic disease performance measurements in primary
care. In fact, several provinces have already published
this information [11,12]. Already in Canada, administra-
tive based performance measures for diabetes care have
been feedback to family physicians as part of the initia-
tives to improve chronic disease management [13].
This study compared a capitation-based remuneration
model to a fee-for service-based model using Canadian
health administrative data to measure key primary care
screening and chronic disease performance indicators.
The preventive care measures include cervical cancer,
breast cancer and colorectal cancer screening. The
chronic diseases include heart failure (HF), diabetes
(DM) and asthma. The specific objectives were: 1) to
provide a cross-sectional comparison of physician per-
formance in FHNs and FHGs; and 2) to compare perfor-
mance before and after physicians joined these first new
primary care groups.
Methods
Study Design
This is a cross-sectional study of performance measures
amongst FHG and FHN physician practices. This is also
a before-after study of performance measures for FHG
and FHN physicians.
Data Sources
Physician demographic data came from the Corporate
Provider Database (CPDB) which provides this informa-
tion on all practicing physicians in Ontario. Patients ros-
tered to a physician participating in a FHG or FHN
were identified using the Client Agency Program Enrol-
ment (CAPE) tables. Information on patient age, sex
and place of residence was obtained from the Ontario’s
Registered Persons Database (RPDB) which is the pro-
vince’s health care registry. All residents of Ontario,
Canada receive coverage from the Ontario Health
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care visits, along their diagnoses and the provision of dif-
ferent types of radiologic services were identified using
physician billing claims to OHIP. All physicians in FHGs
and FHNs continue to submit fee-for-service claims to
OHIP. These OHIP claims are fully paid in FHGs but
only 10% of the claims are paid in FHNs representing the
fee-for-service component of their blended capitation.
Emergency department (ED) visits were extracted from
t h eN a t i o n a lA m b u l a t o r yC a r eR e p o r t i n gS y s t e m
(NACRS) from the Canadian Institute for Health Infor-
mation (CIHI). Prescription claims for all people over 65
years of age in Ontario were identified using the Ontario
Drug Benefit Database (ODB). To identify where patients
live in Ontario, a Statistics Canada’s Postal Code Conver-
sion File was used to assign postal codes of residence to
2001 census dissemination areas.
Study Physicians and Study Patients
All physicians in Ontario who belonged to their first
FHG or FHN for at least two years were identified as
the study physicians. While physicians may join FHGs
or FHNs at different points in time, the study timeframe
was 2004 to 2007. First, we identified the FHG or FHN
to which the physician joined for at least two years (i.e.,
stable FHG or FHN). Then we traced back in time to
determine the first FHG- or FHN-free two-year period
for each physician. Physicians with fewer than 100
patients rostered and FHG or FHN groups with less
than three physicians were also excluded.
Patients were first selected if they were rostered to the
study physician within the two years after the study phy-
sician joined their first stable FHG or FHN. Those
patients that were rostered both in the post-period and
had contact with the physician in the 2 year pre-period
were included. Patients were excluded if they were ros-
tered to multiple physicians or if they died within the
two years after their physician joined a FHG or FHN.
Performance Indicators
The performance measures used in this analysis were
based on available administrative data, and the methods
to derive these measures have been previously published
[11]. The inclusion/exclusion criteria and outcome mea-
sures for each preventive care performance measure are
summarized in Table 1. The eligible patient population,
outcome measure and data source for the chronic dis-
ease performance measures are provided in Table 2. For
the chronic disease performance measures, we identified
all patients rostered to the study physicians who had a
chronic disease in the Ontario Diabetes Database, the
Ontario Asthma Surveillance Information System
( O A S I S )a n db yu s i n gah e a r tf a i l u r ea l g o r i t h md e v e l -
oped at the Institute for Clinical Evaluative Sciences
(ICES). All these chronic disease databases use
algorithms based on hospitalization admission data and
physician visit claims data to identify both incident and
prevalent cases for the entire province of Ontario. In
addition all these chronic disease algorithms have been
validated against physician office records [14-16].
Study patients with incident chronic disease were
those diagnosed with that condition in the first year
after the study physician joined their first stable FHN or
FHG. Study patients with prevalent chronic disease were
those diagnosed with a condition prior to when the
study physician joined their first stable FHN or FHG.
Stratification by age, sex and rurality
All analyses were stratified by age, sex and rurality. Rur-
ality was defined using the Ontario Medical Associa-
tion’s Rurality Index of Ontario (RIO). The RIO is based
on community characteristics including travel time to
different levels of care; community population; presence
of providers, hospitals and ambulance services; social
indicators; and weather conditions [17]. RIO scores
range from zero to one hundred (zero indicating the
most urban and one hundred the most rural). The
Ontario MOHLTC provides a rurality premium pay-
ment to FPs practicing in communities with RIO scores
equal to or greater than 45. Such communities were
then divided into major urban areas (RIO zero to nine),
non-major urban areas (RIO ten to 44) and rural areas
(RIO equal to or greater than 45).
Analyses
For the cross-sectional study, we compared the propor-
tion of a FHG physicians’ practice who received a per-
formance indicator to the proportion of a FHN
physicians’ practice who received a performance indica-
tor. For the before-after study, statistical testing was
undertaken to test the proportion of a performance indi-
cator for a study physicians’ rostered practice before the
physician joined a FHG or FHN group to the proportion
of a performance indicator for the study physicians’ ros-
tered practice after the physician joined a FHG or FHN.
The null hypothesis is that the two proportions are the
same, with p < 0.001 indicating statistical significance.
However, since the sample for the preventive care
measures and some chronic disease measures is high,
there is a lot of power to detect differences that may
not be important at a population health or policy level.
Therefore, in addition to statistical testing, we also con-
sidered a difference of more than 5% to be significant.
Data were accessed through a comprehensive research
agreement between ICES and the MOHLTC. Prior to
data analysis, all patient and provider identifiers were
removed and replaced with unique encrypted numbers.
This study was approved by the Research Ethics Board
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Ontario, Canada.
Results
The characteristics of the study population are provided
in Table 3. During the study time frame (2004 to 2007),
FHNs had approximately one-seventh as many FPs and
o n e - f i f t ha sm a n yg r o u p sa sF H G s .F H N sh a dal a r g e r
proportion of groups in non-major and rural areas than
FHGs. There were no other statistically significant dif-
ferences between FHNs and FHGs.
Preventive Care
While there were statistically significant changes for cer-
vical cancer screening after joining a FHG, there were
no differences greater than 5% (Table 4). There were
significant improvements after joining a FHN for the
three oldest age categories across all regions. The pro-
portion screened both in a FHG or FHN was highest in
the urban areas and lowest in the rural area (p < 0.001).
For both FHN and FHG patients the proportion
screened decreased with age (p < 0.001). FHN patients
compared to FHG patient had a higher proportion for
cervical screening, especially in the rural areas (p <
0.001).
While there were statistically significant changes in
mammography screening after joining a FHG, there
w e r ef e wc h a n g e sg r e a t e rt h a n5 %( T a b l e5 ) .A f t e rj o i n -
ing a FHN, there were statistically significant changes,
but no changes over 5%, with the exception of a 5 to 10
Table 1 Preventive care performance measures using health administrative data
Inclusion Criteria (Denominator) Exclusion criteria Outcome (Numerator)
Cervical
cancer
screening
All women aged 20 to 67 years
rostered to a study physician.
Previous diagnosis of cervical
cancer. Previous history of having
had a hysterectomy.
Received at least one pap smear test over a two year
period.
Breast
cancer
screening
All women aged 50 to 67 years
rostered to a study physician.
Prior history of breast cancer. Received at least one mammogram over a two year period.
Colorectal
cancer
screening
All men and women between 50
and 67 years of age rostered to a
study physician.
Previous diagnosis of colorectal
cancer or inflammatory bowel
disease.
Received either a rigid or flexible sigmoidoscopy, single or
double contract barium enema, colonoscopy or fecal occult
blood test over a two year period.
Table 2 Chronic disease performance measures using health administrative data
Eligible patient population (Denominator) Outcome (Numerator) Data Source
Diabetes
(DM)
Ontario Diabetes
Database
All prevalent DM patients over 30 years of age
rostered to a study physician.
Eligible DM patients who had a claim for an eye examination
over a two year period.
OHIP physician
encounter claims
data.
All incident DM patients rostered to a study
physician over 65 years of age who started on a
hypoglycemic agent.
Eligible DM patients whose first hypoglycemic agent was
metformin.
ODB prescription
claims data.
All prevalent DM patients over 65 years of age
rostered to a study physician.
Eligible DM patients who over one year receive a prescription
for: 1) an ACEI/ARB 2) an antihypertensive agent 3) a lipid
lowering agent 4) all three.
ODB prescription
claims data.
Heart
Failure
(HF)
ICES Heart failure
algorithm
Incident HF patients over 40 years of age
rostered to a study physician.
Eligible HF patients who received an echocardiogram within
one year of diagnosis.
OHIP investigation
claims data.
Incident HF patients over 65 years of age
rostered to a study physician.
Eligible HF patients who received a prescription for an ACEI or
ARB.
ODB prescription
claims data.
Asthma Ontario Asthma
Surveillance
Information System
All incident asthma patients from 20 to 40 years
of age rostered to a study physician.
Eligible asthma patients who received simple spirometry or
flow volume loop or bronchial provocation challenge within
one of diagnosis.
OHIP investigation
claims data.
All incident asthma patients from 20 to 40 years
of age rostered to a study physician.
Eligible asthma patients with emergency room visits within
one year of diagnosis.
NACRS/emergency
room encounter
data.
Jaakkimainen et al. BMC Family Practice 2011, 12:44
http://www.biomedcentral.com/1471-2296/12/44
Page 4 of 15Table 3 Characteristics of study physicians practicing in primary care patient enrollment models
by region and group type
Overall Major Urban Centres Non-Major Urban Centres Rural Centres
FHG
‡ Study Physicians (n) 3466 2586 684 196
Groups (n) 295 185 78 32
Male (n,% ) 64.6 62.8 69.3 70.9
Age (mean, SD) 48.3 (9.5) 48.6 (9.4) 47.2 (9.4) 47.4 (10.1)
Years since graduation (mean, SD) 25.4 (9.8) 25.7 (9.7) 24.3 (9.8) 23.9 (10.4)
Foreign graduation (n,% ) 18.8 20.2 13.7 16.8
Median RIO score (IQR) 4.7 (7.6) 4.2 (3.5) 27.8 (17.1) 55.1 (11.2)
Total number of patients enrolled (mean, std) 957.0 (543.8) 974.3 (541.4) 971.9 (559.2) 676.4 (435.6)
100-299 335 241 57 37
300-649 774 544 155 75
650-999 922 701 180 41
1000-1499 909 689 187 33
1500+ 526 411 105 10
Median Months in Group (IQR) 41.5 (17.6) 40.5 (18.3) 45.0 (13.7) 42.9 (15.5)
FHN
§ Study Physicians (n) 474 212 147 115
Groups (n) 55 22 19 14
Male (n,% ) 66.0 59.4 70.1 73.0
Age (mean, SD) 46.3 (8.7) 46.8 (8.1) 45.4 (9.2) 46.5 (9.3)
Years since graduation (mean, SD) 23.6 (9.1) 24.2 (8.5) 22.6 (9.6) 23.8 (9.2)
Foreign graduation (n, %) 9.7 12.3 7.5 7.8
Median RIO score (IQR) 16.7 (39.2) 4.9 (2.2) 30.2 (22.4) 58.9 (18.3)
Total number of patients enrolled (mean, SD) 995.4 (461.5) 1093.1 (506.9) 1000.1 (435.6) 809.2 (335.0)
100-299 32 16 9 7
300-649 81 27 23 31
650-999 141 51 45 45
1000-1499 148 73 47 28
1500+ 72 45 23 4
Median Months in Group (IQR) 43.0 (11.0) 43.0 (12.5) 46.0 (17.0) 45.0 (7.0)
‡ Family Health Group § Family Health Network
Table 4 Comparison of cervical cancer screening indicators before and after joining a primary care patient enrollment
model by region and group type
Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
FHG
‡ Pap test within 2 years 65.1 67.0* 66.4 68.1*^ 62.0 64.1*^ 53.6 56.3*^
20-29 70.6 72.8* 70.0 72.4* 73.5 74.7* 69.2 71.5
30-39 73.0 74.0* 73.7 74.7*^ 71.8 72.2 63.7 64.8^
40-49 68.8 70.4*^ 70.1 71.7*^ 65.2 67.0*^ 57.8 59.8^
50-59 61.1 61.3^ 63.0 63.1^ 56.3 57.0^ 47.3 48.6^
60-69 46.5 47.5*^ 48.3 49.2*^ 42.5 44.0*^ 35.6 36.4^
FHN
§ Pap test within 2 years 63.4 68.0* 67.6 70.7*^ 61.2 66.9*^ 55.1 62.2*^
20-29 73.9 73.2 74.8 73.3 73.3 74.1 71.4 71.4
30-39 73.2 74.3* 76.0 76.1^ 71.1 72.8 67.5 70.7*^
40-49 66.5 72.3*^ 70.4 75.0*^ 63.3 70.7*^ 59.6 66.9*^
50-59 57.5 62.3*^ 62.4 65.5*^ 54.9 60.4*^ 49.2 56.9*^
60-69 44.1 50.9*^ 48.2 53.9*^ 43.1 50.4*^ 38.2 46.3*^
* p < 0.001 before/after comparison
^ p < 0.001 FHG/FHN comparison
‡ Family Health Group
§ Family Health Network
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69 year age group across all regions. There was a higher
proportion of FHN patients compared to FHG patients
who had mammography screening (p < 0.001).
After joining either a FHN or FHG there was a statis-
tically significant increase for both FHN and FHG
patients in receiving any type of colorectal cancer
screening (Table 6). In the rural regions, colorectal can-
cer screening significantly increased in FHNs compared
with FHGS (p < 0.001). There were no significant
differences between FHNs or FHGs in major urban or
urban regions. For all regions and all age groups, the
greatest increase in colorectal screening was for female
patients (p < 0.001).
Chronic Disease Management
Amongst people newly diagnosed with HF there was lit-
tle change in the ordering of an echocardiogram within
the first year of diagnosis after enrolling in a FHG
(Table 7). After enrollment in a FHG, no significant
Table 5 Comparison of breast cancer screening indicators before and after joining a primary care patient enrollment
model by region and group type
Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
FHG
‡ Mammogram within 2 years 66.6 63.3*^ 66.8 63.5*^ 66.1 63.2*^ 64.7 59.7*^
50-59 66.7 61.5*^ 67.1 61.8*^ 66.2 61.3*^ 63.5 57.4*^
60-69 66.3 66.5^ 66.5 66.7^ 65.9 66.5^ 66.7 63.4*^
FHN
§ Mammogram within 2 years 66.5 68.9*^ 68.3 68.9^ 65.8 67.5^ 63.9 70.8*^
50-59 66.8 66.6^ 68.5 66.9^ 65.7 64.9^ 64.4 68.5*^
60-69 66.0 72.8*^ 67.8 72.7*^ 66.0 71.9*^ 63.1 74.0*^
* p < 0.001 before/after comparison
^p < 0.001 FHG/FHN comparison
‡ Family Health Group
§ Family Health Network
Table 6 Comparison of colorectal cancer screening indicators before and after joining a primary care patient
enrollment model by region and group type
Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
FHG
‡ FOBT 17.4 20.6* 18.3 21.5*^ 16.3 19.5*^ 8.4 10.3*^
Any 24.1 30.4*^ 25.1 31.6* 22.4 28.4*^ 16.0 19.3*^
Male 23.6 29.8*^ 24.7 31.1* 21.5 27.5*^ 16.2 19.4*^
Female 24.6 30.9* 25.5 32.0*^ 23.3 29.3*^ 15.8 19.1*^
50-59 22.9 28.7*^ 23.9 30.0* 20.9 26.4*^ 14.8 17.9*^
Male 22.3 28.0*^ 23.4 29.4* 19.8 25.0*^ 14.8 17.9*^
Female 23.5 29.4* 24.4 30.5*^ 22.0 27.7*^ 14.8 17.9*^
60-69 26.2 33.3*^ 27.2 34.5* 24.8 31.7*^ 17.8 21.3*^
Male 25.9 32.8*^ 27.0 34.1* 24.2 31.4*^ 18.3 21.6*^
Female 26.5 33.6* 27.4 34.9*^ 25.4 32.0*^ 17.3 20.9*^
FHN
§ FOBT 12.9 20.5* 14.6 23.2*^ 10.0 17.9*^ 12.9 18.0*^
Any 19.3 29.0*^ 20.8 32.0* 16.8 25.8*^ 19.7 26.9*^
Male 18.8 26.9*^ 20.3 30.3* 16.3 23.8*^ 19.1 24.1*^
Female 19.8 30.9* 21.1 33.5*^ 17.4 27.8*^ 20.2 29.5*^
50-59 18.1 27.3*^ 19.4 30.3* 16.0 24.1*^ 18.3 24.7*^
Male 17.3 24.9*^ 18.7 28.6* 15.3 21.5*^ 17.1 21.4*^
Female 18.9 29.4* 19.9 31.7*^ 16.8 26.6*^ 19.4 27.8*^
60-69 21.3 31.9*^ 23.4 35.3* 18.1 28.8*^ 21.5 29.7*^
Male 21.2 30.2*^ 23.4 33.4* 17.9 27.7*^ 21.5 27.6*^
Female 21.4 33.5* 23.5 36.9*^ 18.3 29.8*^ 21.4 31.7*^
* p < 0.001 before/after comparison
^p < 0.001 FHG/FHN comparison
‡ Family Health Group
§ Family Health Network
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region and group type
Measure Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
FHG
‡ Echocardiogram - 1 year
40-64 53.0 54.8 54.4 56.9 51.7 51.5^ 42.2 42.5
Male 55.2 56.6 56.3 59.1 54.5 53.5 45.5 40.3
Female 49.6 52.0 51.5 53.6 47.4 48.6 37.9 47.2
65-74 47.2 50.1 48.3 52.2 46.8 46.0 38.8 42.3
Male 48.8 52.8 50.5 55.3 47.4 48.2 37.0 43.4^
Female 45.3 47.1 45.6 48.9 46.1 43.6 40.5 41.1
75+ 37.6 38.5 38.9 40.1 36.1 36.6 30.5 28.6
Male 39.9 42.3 40.6 44.9 40.2 39.8 31.8 25.0
Female 35.9 35.4 37.6 36.2 33.2 34.1 29.5 31.7
Overall 45.0 45.6^ 46.2 47.6 43.8 42.7 36.8 35.6
Male 48.1 49.2 49.2 51.8 47.6 45.8 37.9 34.3
Female 41.8 41.9^ 43.1 43.2 40.0 39.6 35.8 37.0
ACE Inhibitor - 1 year
65-74 68.7 64.0* 67.9 64.4 70.7 62.5*^ 68.5 65.8
Male 73.5 69.4* 72.4 70.0 75.5 67.1* 76.5 71.1^
Female 63.1 58.1* 62.6 58.2 65.0 57.2 60.7 60.3
75 and older 65.3 60.6* 66.1 61.7* 63.0 59.0 66.7 55.3
Male 68.9 65.4* 70.0 66.0* 66.0 63.7 68.2 65.3
Female 62.8 56.7* 63.2 58.1* 60.9 55.4 65.6 46.5*
Overall 66.8 61.8* 66.9 62.6* 66.3 60.2*^ 67.5 59.0*
Male 71.1 66.9* 71.2 67.6* 70.7 65.0* 72.2 67.5
Female 62.9 57.1* 63.0 58.1* 62.4 55.9*^ 63.6 51.2*
FHN
§ Echocardiogram - 1 year
40-64 13.0 50.8* 49.2 59.6 42.4 40.2^ 49.5 50.7
Male 28.4 54.6* 51.9 65.0 42.4 44.2 48.2 52.5
Female 19.0 45.5* 45.1 52.3 42.4 34.3 51.0 48.5
65-74 14.8 51.4* 54.9 49.1 43.0 50.0 47.2 55.0
Male 28.5 54.1* 51.3 48.3 50.0 53.3 50.8 60.0^
Female 20.4 47.9* 59.1 50.0 32.6 46.0 42.6 47.7
75+ 31.9 34.6 36.9 35.5 25.8 32.1 29.9 36.0
Male 33.7 40.5 40.9 41.3 22.6 34.7 32.1 44.0
Female 30.6 30.8 33.9 31.4 27.8 30.7 28.4 30.0
Overall 41.6 42.4^ 45.7 43.9 36.4 38.8 40.9 44.3
Male 44.3 48.3 47.8 49.6 40.1 43.7 43.6 51.0
Female 38.8 37.1^ 43.5 38.7 32.3 34.8 38.2 37.7
ACE Inhibitor - 1 year
65-74 69.6 64.5 68.3 63.9 73.7 72.7^ 67.0 56.9
Male 71.9 66.5 69.7 70.0 75.0 76.7 71.2 53.8^
Female 66.7 62.0 66.7 56.3 71.7 68.0 61.7 61.4
75 and older 69.4 62.8 71.5 63.4 71.2 63.6 64.2 61.1
Male 74.8 69.7 76.3 69.4 81.1 66.7 66.1 72.5
Female 65.5 58.2 67.8 59.2 64.6 62.0 63.0 52.5
Overall 69.5 63.4 70.2 63.6 72.4 66.8^ 65.4 59.7
Male 73.3 68.4 73.4 69.6 77.7 71.2 68.7 64.7
Female 65.9 59.2 67.4 58.5 67.2 63.6^ 62.5 54.9
* p < 0.001 before/after comparison
^ p < 0.001 FHG/FHN comparison
‡ Family Health Group
§ Family Health Network
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Page 7 of 15change was seen with either men or women, in all age
groups and in all regions. However, after enrollment in
a FHN, the proportion of HF patients receiving an echo-
cardiogram significantly increased to 50% for those 40
to 64 years of age and to 51% for those between 65 and
74 years of age. This increase in the proportion receiv-
ing an echocardiogram was higher amongst women than
men in these age groups (p < 0.001). There were no dif-
ferences amongst FHNs located in major urban, non-
major urban or rural centres. There were no significant
differences between FHNs and FHGs in their HF
patients receiving an echocardiogram.
After enrolling in a FHG or FHN, there was a statisti-
cally significant decrease of 5% to 6% in the proportion
of newly diagnosed HF patients receiving a prescription
for an ACEI. This slight decrease was similar amongst
men and women, between different age groups and
between FHGs and FHNs located in major urban, non-
major urban or rural centres. There were no differences
between FHNs and FHNs with respect to prescribing
ACEIs.
Amongst patients newly diagnosed with DM there was
a statistically significant increase with all prescribing
indicators after enrolling in either a FHG or a FHN
(Table 8 and Table 9). For FHGs, there was an 12%
increase in people receiving a prescription for metfor-
min, a 9% increase in receiving a prescription for a lipid
lower agent, a 5% increase in receiving a prescription
for an ACEI and an 8% increase in receiving all three
cardiovascular medications (ACEI, lipid lower agent and
antihypertensive)(p < 0.001). There was only a 3%
increase in receiving an antihypertensive medication.
For FHNs, there was a 15% increase in DM patients
receiving a prescription for a lipid lowering agent, a 14%
increase in receiving a prescription for metformin, a
10% increase in receiving a prescription for an ACEI
and a 12% increased in receiving all three cardiovascular
medications (ACEI, lipid lower agent and antihyperten-
sive medication) (p < 0.001). There was a modest,
though statistically significant increase with antihyper-
tensive medication (6%) prescribing. For both FHGs and
FHNs these increases were similar between men and
women, at all age groups and between major urban,
non-major urban and rural centres. There were no sig-
nificant differences between FHNs and FHGs.
A f t e re n r o l l i n gi naF H Gt h e r ew a sa no v e r a l l1 5 %
decrease and after enrolling in a FHN a 14% decreased
in the proportion of DM patients having an annual eye
examination (p < 0.001). This decrease was highest
amongst people with DM less than 65 years of age (27%
and 29%) compared with people over 65 years of age
(about 2%). The decrease was similar between men and
women and between major urban, non-major urban and
rural centres.
After joining either a FHG or FHN, for people with
newly diagnosed asthma (Table 10) there were no statis-
tically significant changes in spirometry testing and
emergency department (ED) visits within one year of
diagnosis. There was no statistically significant change
after joining a FHG of FHN for both men and women,
by all age groups and for FHG practices in major urban,
non-major urban and rural centres. There were no sig-
nificant differences between FHGs and FHNs for the
asthma performance measures.
Discussion
Several factors may influence chronic disease manage-
ment in family medicine. For example, practices located
in rural regions are challenged by less availability and
access to technology or specialty care to help diagnose
or monitor some conditions. For chronic diseases, this
may affect some aspects of patient care such as echocar-
diogram and spirometry testing and ophthalmologic
assessment. Physician knowledge, experience or comfort
in managing chronic disease may influence medical
therapy that their patients receive, such as medications.
Practice structures can facilitate chronic disease man-
agement through processes such as interdisciplinary
care. Physician remuneration models and pay for perfor-
mance incentives may improve benchmark levels of
chronic disease performance measures.
The results for the HF and DM prescribing indicators
are similar to those measured in other studies con-
ducted in Canada [11,18,19]. Benchmark prescribing
levels for HF patients are usually based on patients dis-
charged from hospital and do not include HF patients
diagnosed and managed outside of the hospital setting
[20]. Quality of care for DM management has focused
on clinical targets and less so on providing specific pre-
scribing benchmarks [21]. Nevertheless, the prescribing
levels for HF and DM patients in this study approach
some evidence based targets. While the HF and DM
prescribing indicators did not significantly differ from
patients belonging to a FHG versus a FHN, some pre-
scribing indicators did differ slightly (of around 5%) by
region in Ontario. However, further work which would
control for potential confounders such as socioeconomic
status and comorbidity still needs to be done to confirm
these comparisons.
Since 2002, several clinical evidence-based guidelines
have been disseminated to primary care practitioners for
DM management [21,22]. In this analysis, after patients
enrolled in either a FHG or FHN model, improvements
were seen in the prescribing of metformin, angiotensin
converting enzyme inhibitor (ACEI) and antilipid medi-
cations. This may be a result of incentive payments for
DM care. It may also reflect the success in knowledge
translation of evidence based care for DM. Interestingly,
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Page 8 of 15Table 8 Comparison of diabetes mellitus indicators before and after joining Family Health Groups by region
Measure Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
Eye Examination - 2 years
30-39 55.6 28.7* 54.3 28.6* 59.9 28.7* 61.7 29.0*
Male 51.9 29.1* 50.9 29.2* 55.7 28.4* 56.5 31.0*
Female 58.0 28.4* 56.6 28.3* 62.5 28.9* 65.2 27.5*
40-64 69.8 42.6* 69.3 43.2* 71.9 41.2* 69.1 38.7*
Male 67.4 41.1* 67.0 41.6* 69.5 39.8* 66.5 37.6*
Female 72.6 44.4* 72.0 45.0* 74.9 42.8* 72.2 40.0*
65-74 82.7 82.6 82.1 82.0 84.6 84.5 84.8 83.9
Male 81.5 81.2 80.9 80.5 83.4 83.4 82.8 82.0
Female 84.1 84.2 83.3 83.6 86.1 85.8 87.0 86.0
75+ 83.3 81.8 82.6 80.9 85.4 84.2 85.0 83.7
Male 84.0 82.5 83.4 81.6 85.7 85.0 85.4 83.8
Female 82.8 81.2 81.9 80.3 85.2 83.6 84.6 83.6
Overall 74.5 59.8* 73.7 59.3* 77.1 61.4* 76.0 60.5*
Male 72.8 58.4* 72.1 57.9* 75.3 60.1* 73.7 58.9*
Female 76.3 61.2* 75.5 60.8* 79.1 62.7* 78.5 62.3*
Metformin - 1 year
65-74 75.3 88.3* 74.3 88.7* 78.1 87.0* 76.5 87.6*
Male 74.2 85.9* 72.4 86.2* 78.6 85.3* 77.2 85.5*
Female 76.3 90.4* 76.0 91.0* 77.6 88.8 75.6 89.4*
75 and older 73.9 84.1* 73.8 83.4* 74.4 84.4* 72.3 90.3*
Male 75.5 84.3* 75.0 83.0 78.9 86.8* 64.3 89.7*
Female 72.8 83.9* 73.0 83.7* 71.5 82.6* 75.8 90.7*
Overall 74.8 86.7* 74.1 86.7* 76.8 86.0* 75.2 88.6*
Male 74.6 85.4* 73.2 85.1* 78.7 85.8* 74.6 86.9*
Female 75.0 87.8* 75.0 88.1* 75.1 86.2* 75.7 89.9*
ACE inhibitor - 1 year
65-74 67.5 72.5* 67.6 72.5* 66.9 73.0* 67.6 72.0*
Male 68.0 73.5* 68.2 73.4* 67.6 73.9* 67.4 72.8*
Female 66.9 71.5* 67.0 71.4 66.2 71.8 67.8 71.0
75 and older 66.1 71.5* 66.6 72.0* 64.9 70.6 64.2 68.4
Male 65.8 71.3* 66.4 71.9 64.6 70.2 62.9 67.1
Female 66.4 71.8* 66.8 72.2 65.2 70.9 65.3 69.6
Overall 67.0 72.1* 67.3 72.3* 66.2 71.9* 66.3 70.4*
Male 67.3 72.6* 67.6 72.8* 66.6 72.5* 65.8 70.5*
Female 66.7 71.6* 66.9 71.7* 65.7 71.4* 66.7 70.4*
Antihypertensive agent - 1 year
65-74 64.9 67.7 64.4 67.1* 65.6 69.0* 68.3 70.7
Male 63.0 66.2 62.7 65.8* 63.4 66.8* 66.2 69.0
Female 66.9 69.4 66.4 68.6 68.1 71.7 70.6 72.8
75 and older 73.8 76.6* 73.5 76.2 74.2 77.1 76.8 80.0*
Male 70.6 74.0 70.4 73.7 70.6 74.1 73.1 77.3
Female 76.3 78.7 75.9 78.3 76.9 79.5 79.8 82.3
Overall 68.2 71.4* 67.7 70.9* 68.9 72.5* 71.6 74.8*
Male 65.5 69.2* 65.2 68.8* 65.8 69.6* 68.6 72.3*
Female 70.8 73.7* 70.2 72.9* 71.9 75.5* 74.6 77.3
Lipid-lowering agent - 1 year
65-74 59.3 67.9* 59.9 68.5* 57.5 66.4* 57.2 65.5*
Male 60.2 69.0* 60.7 69.4* 58.9 68.0* 58.5 67.3*
Female 58.2 66.7* 59.0 67.4* 56.0 64.4 55.8 63.3
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Page 9 of 15while the prescribing of antihypertensive medications
had not reached benchmark levels, we did not see a sig-
nificant change after patients enrolled in either FHGs or
FHNs.
In this analysis, there were no significant changes in
ACEI prescribing for HF patients after they enrolled in
either a FHG or FHN model. The HF management
incentives for FHGs and FHNs were introduced in 2008,
a f t e rt h es t u d yt i m ef r a m e .A l t h o u g he v i d e n c e - b a s e d
guidelines have been developed by the Canadian Cardi-
ology Association for the management of HF patients,
their dissemination into primary care practice has been
limited [20]. Rather than concluding a lack of affect of
primary care delivery models affecting HF management,
our study may point to a lack of knowledge translation
of the current HF recommendations into primary care.
Follow up work, after the HF management incentives
were implemented, may better demonstrate any poten-
tial impact they may have in the care of HF patients.
More striking gender and age differences were found.
We found lower echocardiogram use and ACEI pre-
scribing for women newly diagnosed with HF and lower
ophthalmology use for DM patients less than 64 years
of age. For several reasons, women receive fewer cardio-
vascular investigations than men [23,24]. As of Novem-
ber 1 2004, funding for routine eye examinations by
either an optometrist or physician for patients between
20 and 64 years of age was no longer covered under the
publically funded health insurance plan. However,
patients of all ages with stipulated medical conditions,
such as DM are still eligible for an annual eye examina-
tion. It may be that younger DM patients and their FPs
are unaware of this coverage and this may be one reason
for poorer referrals for younger DM patients.
There were no improvements in our performance
measures for asthma care and no asthma management
incentives exist for either model. While asthma guide-
lines exist for FPs, the emphasis on evidence-based clini-
cal care often focuses on the medications prescribed for
people with asthma and less so on health administrative
data indicators such as spirometry testing and emer-
gency room use as used in this study [25]. Further ana-
lysis should include an examination of medication use
by people with asthma.
While the proportion or women getting mammogra-
p h yo rp a ps m e a rt e s t i n gw a sh i g h e ra m o n g s tt h o s e
belonging to a FHN versus a FHG, the differences were
not large. The capitation remuneration payment for FPs
participating in FHN models may account for this slight
improvement. In Ontario, benchmark mammography
and pap smear testing levels are generally set at 75% for
screen eligible women [26]. In this study, both mammo-
graphy and pap smear testing met or approached these
levels, regardless of the physician remuneration struc-
ture or practice location. However, secular trends in
Ontario for mammography and pap smear testing prior
to the introduction of these new primary care models
were already approaching benchmark levels [11].
Although the proportion of the study patients receiving
colorectal screening is still low, it did improve signifi-
cantly after patients joined either a FHG and FHN, and
in comparison to similar provincial results released in
2006 [11]. No differences were seen in colorectal screen-
ing between FHGs and FHNs. In March 2008, after the
Table 8 Comparison of diabetes mellitus indicators before and after joining Family Health Groups by region
(Continued)
75 and older 50.1 59.4* 52.2 60.8 44.4 55.8 45.1 53.7
Male 51.0 61.1* 52.8 62.3* 46.2 58.1 46.3 56.4
Female 49.5 58.0* 51.8 59.6 43.0 54.0 44.1 51.4
Overall 55.9 64.3* 57.1 65.3 52.5 61.8* 52.5 60.3*
Male 57.2 66.0* 58.1 66.7* 54.7 64.2* 54.2 62.9*
Female 54.6 62.7* 56.1 63.9 50.4 59.4* 50.8 57.6*
All three - 1 year
65-74 35.4 43.0* 35.7 43.2* 34.0 42.4* 36.8 43.0*
Male 36.0 43.9* 36.3 44.2 34.7 43.0* 37.0 43.8
Female 34.8 42.0* 35.1 42.1* 33.3 41.6 36.5 42.0*
75 and older 32.4 40.4* 33.7 41.5 28.6 38.1* 28.5 35.5
Male 32.4 41.0* 33.6 42.1* 29.1 38.6 28.6 36.1*
Female 32.4 39.9* 33.9 41.0 28.2 37.6 28.5 35.0
Overall 34.3 41.9* 35.0 42.5* 32.0 40.5* 33.6 39.7*
Male 34.8 42.8* 35.4 43.4* 32.8 41.3* 34.0 40.7*
Female 33.8 41.1* 34.6 41.6* 31.1 40.0* 33.1 38.7*
* p < 0.001 before/after comparison.
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Page 10 of 15Table 9 Comparison of diabetes mellitus indicators before and after joining Family Health Networks by region
Measure Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
Eye Examination - 2 years
30-39 64.4 34.1* 66.8 35.3* 62.0 35.6* 61.4 28.5*
Male 59.4 34.6* 63.2 34.5* 58.6 36.7* 51.7 31.6*
Female 68.0 33.8* 69.3 35.9* 64.8 34.9* 68.8 26.5*
40-64 73.9 46.1* 74.4 45.8* 73.4 46.9* 73.6 45.6*
Male 71.5 45.2* 72.1 45.1* 71.5 46.6* 70.3 43.5*
Female 76.9 47.2* 77.2 46.6* 75.9 47.3* 77.5 48.0*
65-74 83.9 85.5* 84.4 85.6 82.6 85.9 84.5 84.8
Male 82.4 84.1 82.6 84.1 81.7 84.5 82.9 83.6
Female 85.6 87.1 86.5 87.3 83.7 87.6 86.3 86.3
75+ 86.0 84.0 85.7 84.7 85.9 83.6 86.5 83.2
Male 85.2 85.6 84.1 85.8 86.0 86.9 86.3 83.9
Female 86.5 82.6 86.8 83.8 85.9 80.9 86.7 82.6
Overall 78.2 64.6* 78.4 63.4* 77.5 64.7* 78.5 65.7*
Male 76.0 63.6* 76.1 62.4* 74.0 64.3* 75.9 65.0*
Female 80.5 65.1* 80.8 64.4* 79.4 65.2* 81.3 66.5*
Metformin - 1 year
65-74 68.5 86.7* 64.8 86.6* 77.8 85.1* 66.2 88.2*
Male 77.0 84.3* 77.5 83.3 81.8 87.5 73.7 82.9
Female 61.2 89.5* 54.9 90.7* 75.0 82.9 57.6 96.3
75 and older 69.2 83.2* 66.1 82.8* 64.5 83.6* 80.0 83.3
Male 73.1 80.6* 69.2 71.4 75.0 88.0 78.6 81.3
Female 66.2 84.9* 63.3 88.4* 57.9 80.0 81.3 85.0
Overall 68.8 85.3* 65.3 85.1* 72.9 84.4* 70.3 86.5*
Male 75.7 83.1* 74.2 80.0 79.4 87.7 75.0 82.5
Female 63.0 87.4* 58.0 89.5* 68.6 81.5 65.3 91.5*
ACE inhibitor - 1 year
65-74 61.2 71.1* 61.1 70.9* 63.4 72.6* 59.0 69.7*
Male 62.0 71.7* 61.6 71.7* 64.4 73.6* 59.9 69.9*
Female 60.3 70.2* 60.5 70.0* 62.2 71.4 57.9 69.4*
75 and older 58.9 68.9* 58.5 69.5* 60.3 70.2* 58.0 66.5*
Male 57.4 69.1* 55.8 69.7* 61.1 71.8 55.8 65.2*
Female 60.0 68.8* 60.4 69.3* 59.8 68.9* 59.7 67.6
Overall 60.4 70.1* 60.1 70.3* 62.2 71.5* 58.6 68.4*
Male 60.5 70.7* 59.8 70.9* 63.4 72.9* 58.7 68.2*
Female 60.2 69.5* 60.5 69.7* 61.1 70.2* 58.6 68.5*
Antihypertensive agent - 1 year
65-74 64.9 68.0* 63.8 68.0* 68.1 69.2 63.0 66.7
Male 61.2 65.7* 60.9 66.4 64.5 67.1 58.2 63.3
Female 68.5 70.7* 66.7 69.8 71.5 71.7 68.0 71.1
75 and older 71.0 75.0* 69.0 74.5* 75.7 76.1 68.6 74.5
Male 67.4 72.2* 65.9 71.8 72.6 71.6 64.2 73.5
Female 73.6 77.3* 71.3 76.6* 77.9 79.7 72.1 75.5
Overall 64.9 71.1* 63.8 71.0* 68.1 72.2* 63.0 69.9*
Male 61.2 68.2* 60.9 68.6* 64.5 68.9* 58.2 67.0*
Female 68.5 73.9* 66.7 73.2* 71.5 75.6* 68.0 73.1
Lipid-lowering agent - 1 year
65-74 47.3 63.5* 50.5 67.2* 47.0 60.8* 42.9 60.6*
Male 47.8 64.8* 51.9 69.6* 46.3 61.9* 43.2 61.0*
Female 46.7 61.8* 48.8 64.4* 47.8 59.4* 42.5 60.2*
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Page 11 of 15time frame of this study, a new Cancer Care Ontario
colorectal screening program was launched, which
included more financial incentives to improve colorectal
screening benchmarks [27]. Further comparison with
primary care models which do not have incentive pay-
ments may expand the understanding of the impact of
these initiatives on colorectal cancer screening rates. In
England, an examination of 18 general practices found
that financial incentives introduced to improve quality
of care for “incentivized” conditions and non-"incenti-
vized” conditions did not demonstrate any quality
improvement [28]. Similarly another study, based in the
UK, found that the quality of care for asthma, diabetes
and coronary artery disease was improving before the
introduction of 2004 pay for performance incentives.
However, it did conclude there was a modest accelera-
tion in quality improvement for diabetes and asthma
after 2004 [29]. Another British study, which examined
preventive prescribing indicators and the health gains
related to potential payments (including incentive pay-
ments), found no relationship between pay and health
gain across the prescribing interventions examined [30].
A retrospective review of a US Medicare community
health centre population which used administrative data
to measure performance did not find evidence of clini-
cally significant change with financial incentives for pre-
ventive care performance [31]. Another US study of 35
Kaiser Permanente facilities found the removal of finan-
cial incentives was associated with decreased DM retino-
pathy screening and cervical cancer screening [32].
A systematic review of studies examining pay for per-
formance confirms that the results of pay for perfor-
mance range from extremely positive to disappointing
[33]. Among the recommendations made to ensure suc-
cess with the selection of pay for performance incentives
are the selection and definition of pay for performance
targets on the basis of baseline room for improvement.
This may be the situation for breast cancer and cervical
cancer screening activity in Ontario. Prior to the intro-
duction of FHGs and FHNs, these screening rates were
approaching 75% [11]. Colorectal cancer screening rates
were extremely low prior to the introduction of FHNs
and FHG, and therefore incentive payments, along with
other provincial strategies, may have contributed to the
improvements seen in screening rates.
There are several limitations to our study. First, this
study was limited to enrolled patients, and as the num-
bers continue to rise as more patients enroll in FHGs,
FHNs and other models further research would be war-
ranted. In some cases, the period of time over which the
indicator was measured was insufficient. For example, a
two and half year window for determining mammogra-
phy screening may be more appropriate than two years.
Using administrative data alone poses challenges in
assessing quality of care. For example, getting a pre-
scription for a medication is not the same as actually
taking it. And finally tracking FP care is challenging in
Canada, as FPs may participate in more than one type
or primary care model.
Conclusions
Some improvements in preventive screening and DM
management were seen amongst people after they
enrolled in a FHG or FHN. FHNs, a capitation-based
model, demonstrated some improvements in care, espe-
cially in rural regions. To some degree these
Table 9 Comparison of diabetes mellitus indicators before and after joining Family Health Networks by region
(Continued)
75 and older 38.5 53.2* 40.5 56.8 37.0 49.8* 36.7 50.6
Male 40.9 57.6* 41.3 59.5* 41.9 56.2* 39.2 55.9
Female 36.7 49.7* 39.9 54.8 33.7 44.7 34.7 46.0
Overall 44.1 58.9* 46.7 62.5* 43.2 55.9* 40.8 56.5*
Male 45.7 62.0* 48.5 65.5* 45.0 59.7* 42.0 59.1*
Female 42.5 55.9* 45.0 59.6* 41.5 52.1* 39.5 53.6*
All three - 1 year
65-74 25.7 39.5* 27.2 41.7* 26.4 39.1* 22.8 36.5*
Male 25.7 40.1* 27.9 42.8* 25.8 40.3* 22.3 36.2*
Female 25.7 38.7* 26.3 40.4* 27.1 37.8* 23.3 36.8*
75 and older 22.5 35.4* 23.9 37.8* 21.7 33.9* 21.0 33.0
Male 23.3 37.4* 22.1 38.0* 25.5 37.3* 22.8 36.5*
Female 21.9 33.8* 25.1 37.6* 19.1 31.1 19.5 29.9
Overall 24.5 37.7* 25.9 39.9* 24.6 36.8* 22.2 35.0
Male 24.9 39.1* 26.0 40.9* 25.7 39.1* 22.4 36.3*
Female 24.1 36.3* 25.8 39.0* 23.5 34.5* 21.9 33.6
* p < 0.001 before/after comparison
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Page 12 of 15Table 10 Comparison of asthma indicators before and after joining a primary care patient enrollment model, by
region and group type
Measure Overall Major Urban Centres Non-Major Urban Centres Rural Centres
Before After Before After Before After Before After
FHG‡ Spirometry test - one year
10 to 19 32.1 34.2 31.9 34.6 31.8 33.5 37.2 30.4^
Male 30.9 34.0 30.0 33.8 32.3 35.6 39.0 28.6
Female 32.8 34.4 33.1 35.3 31.5 32.2 35.8 31.8^
20 to 29 31.7 33.7 33.1 33.2 28.1 36.0* 19.2 34.1
Male 32.8 33.0 33.4 32.9 30.9 33.8 26.7 31.3
Female 31.1 34.1 32.9 33.3 27.1 37.0* 16.2 36.0
30 to 39 33.0 33.4 31.6 32.3 39.7 40.1 26.3 20.4
Male 34.4 34.7 32.2 34.2 45.1 37.9 22.2 33.3
Female 32.2 32.7 31.2 31.3 36.9 41.1 27.6 17.5
Overall 32.3 33.8 32.1 33.4 33.5 36.2 29.3 28.4^
Male 32.7 34.0 31.7 33.7 36.3 35.9 32.4 30.0
Female 32.1 33.6 32.3 33.2 32.1 36.4 27.7 27.5^
Emergency Department Visit
10 to 19 7.9 8.4 5.9 6.7 12.7 11.8 14.9 19.0
Male 6.6 7.8 4.5 6.1 11.8 11.0 12.2 20.0
Female 8.7 8.8 6.8 7.2 13.3 12.3 17.0 18.2
20 to 29 10.4 8.2^ 9.5 6.7* 12.8 12.3 17.3 24.4
Male 10.0 6.8 8.2 4.8* 16.0 11.3 26.7 31.3
Female 10.5 8.9 10.1 7.6^ 11.7 12.7 13.5 20.0
30 to 39 8.0 7.2^ 6.4 6.0 13.1 10.0 18.4 28.6
Male 6.9 6.4 5.5 5.9 11.6 7.8 16.7 22.2
Female 8.6 7.6 6.8 6.0 13.8 11.0 19.0 30.0
Overall 8.6 8.0^ 7.0 6.5^ 12.8 11.4 16.7 23.1
Male 7.5 7.2 5.8 5.9 12.5 10.1 16.2 23.3
Female 9.2 8.4^ 7.7 6.9^ 13.0 12.1 16.9 22.9
FHN§ Spirometry test - one year
10 to 19 35.8 39.4 30.8 36.8 40.0 36.1 42.9 52.4^
Male 31.0 37.1 24.2 39.1 38.7 32.1 38.9 40.0
Female 39.6 40.8 36.5 35.0 41.0 38.2 44.7 59.3^
20 to 29 31.7 37.9 27.2 37.5 32.8 34.5 44.4 46.7
Male 40.3 28.6 38.5 18.8 31.8 37.5 63.6 50.0
Female 27.2 40.9 21.3 42.9* 33.3 33.3 36.0 45.5
30 to 39 37.1 39.9 36.7 42.1 33.7 36.5 44.7 38.1
Male 43.8 37.7 41.1 40.7 48.3 31.6 45.0 42.9
Female 33.5 40.9 34.5 42.6 26.3 39.4 44.4 35.7
Overall 35.3 39.2 32.0 38.8 36.7 36.0 43.9 47.4^
Male 36.8 35.9 32.3 36.0 39.8 32.7 46.9 42.3
Female 34.4 40.9 31.8 40.2 34.7 37.6 42.2 50.0^
Emergency Department Visit
10 to 19 11.1 10.4 7.2 6.6 13.1 15.7 19.6 9.5
Male 13.5 6.7 9.9 6.5 17.7 7.1 16.7 6.7
Female 9.3 12.7 4.8 6.7 9.6 20.0 21.1 11.1
20 to 29 14.9 19.8^ 10.5 19.4 13.8 13.8 30.6 33.3
Male 2.8 10.7 6.3 4.5 12.5 9.1 25.0
Female 21.3 22.7 16.0 23.2^ 19.4 14.3 40.0 36.4
30 to 39 10.9 13.7^ 5.9 9.5 14.0 15.4 23.4 28.6
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Page 13 of 15improvements may be attributed to incentive payments
offered within FHGs and FHNs. However, these primary
care delivery models need to be compared with other
primary care delivery models such as Family Health
Organizations (FHOs), Family Health Teams (FHTs),
Community Health Centres (CHCs) and fee for service
practices in order to fully describe more specifically
what aspects of model delivery and incentives affect
care.
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